CCRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Cross Country Healthcare Inc (CCRN) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are positive analyst upgrades and a strategic pivot, the financial performance shows significant revenue decline, and the stock's short-term trend indicates potential further downside. Given the lack of strong trading signals and no recent news catalysts, it is better to hold off on buying this stock for now.
The MACD is positive and expanding, suggesting mild bullish momentum. However, RSI is neutral at 62.545, and moving averages are converging, indicating no clear trend. The stock is trading near its resistance level (R1: 9.933), and the next support level is at 8.921. Short-term candlestick analysis suggests a 90% chance of further downside (-1.1% next day, -2.53% next week, -3.16% next month).
Analyst upgrades from Wedbush and Benchmark with increased price targets ($15 and $14, respectively).
Strategic pivot to tech-enabled staffing and improved EBITDA margin targets.
Debt-free balance sheet with $119M liquidity for strategic investments.
Significant revenue decline (-23.61% YoY in Q4 2025).
Short-term stock trend indicates further downside.
No recent news or congress trading data to support a positive sentiment shift.
In Q4 2025, revenue dropped significantly by -23.61% YoY to $236.76M. However, net income and EPS improved dramatically, albeit still negative (-$82.93M net income, -$2.56 EPS). Gross margin slightly increased to 18.65%. Overall, financials reflect a mixed picture with ongoing challenges.
Recent upgrades from Wedbush (Outperform, $15 PT) and Benchmark (Buy, $14 PT) highlight optimism about revenue stabilization, profitability recovery, and strategic pivot. UBS remains Neutral with a $10 PT, citing confidence in EBITDA margin targets but cautious on growth.
